Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.

doi:10.1186/s13046-018-0820-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.

Journal of experimental & clinical cancer research : CR - 9 Jul 2018

Del Curatolo Anais, Conciatori Fabiana, Cesta Incani Ursula, Bazzichetto Chiara, Falcone Italia, Corbo Vincenzo, D'Agosto Sabrina, Eramo Adriana, Sette Giovanni, Sperduti Isabella, De Luca Teresa, Marabese Mirko, Shirasawa Senji, De Maria Ruggero, Scarpa Aldo, Broggini Massimo, Del Bufalo Donatella, Cognetti Francesco, Milella Michele, Ciuffreda Ludovica

Abstract excerpt

BACKGROUND: Mounting evidence suggests that RAF-mediated MEK activation plays a crucial role in paradox MAPK (re)activation, leading to resistance and therapeutic failure with agents hitting a single step along the MAPK cascade. METHODS: We examined the molecular and functional effects of single and combined BRAF (dabrafenib), pan-RAF (RAF265), MEK (trametinib) and EGFR/HER2 (lapatinib) inhibition, using Western...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to EGFR gene

Share to Mice

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 29986755
DOI: 10.1186/s13046-018-0820-5
PMCID: PMC6038340

Genes

BRAF
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.PMID 29986755Read ↗

RAF inhibitors that evade paradoxical MAPK pathway activation.Semantic proximity Read ↗

Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Semantic proximity Read ↗

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancerSemantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Semantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

MEK and RAF inhibitors for BRAF-mutated cancersSemantic proximity Read ↗

Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.Semantic proximity Read ↗

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.Semantic proximity Read ↗

Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.Semantic proximity Read ↗

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.Semantic proximity Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.